Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Prognostic significance of miR-215 in colon cancer.

Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, Burke S, Shroyer K, Ju J.

Clin Colorectal Cancer. 2011 Dec;10(4):340-7. doi: 10.1016/j.clcc.2011.06.002. Epub 2011 Jul 12.

2.

Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.

Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J.

Mol Cancer. 2010 Apr 30;9:96. doi: 10.1186/1476-4598-9-96.

3.

MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.

Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zöllner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W, Hahn SA.

Carcinogenesis. 2012 Apr;33(4):732-9. doi: 10.1093/carcin/bgs020. Epub 2012 Jan 27.

PMID:
22287560
4.

Clinical significance of microRNA-93 downregulation in human colon cancer.

Xiao ZG, Deng ZS, Zhang YD, Zhang Y, Huang ZC.

Eur J Gastroenterol Hepatol. 2013 Mar;25(3):296-301. doi: 10.1097/MEG.0b013e32835c077a.

PMID:
23354160
5.

Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma.

Li L, Sarver AL, Khatri R, Hajeri PB, Kamenev I, French AJ, Thibodeau SN, Steer CJ, Subramanian S.

J Pathol. 2014 Dec;234(4):488-501. doi: 10.1002/path.4407. Epub 2014 Oct 1.

PMID:
25269767
6.

Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance.

Gopalan V, Pillai S, Ebrahimi F, Salajegheh A, Lam TC, Le TK, Langsford N, Ho YH, Smith RA, Lam AK.

Mol Carcinog. 2014 Feb;53 Suppl 1:E36-44. doi: 10.1002/mc.21993. Epub 2013 Sep 5.

PMID:
24009195
7.

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC.

JAMA. 2008 Jan 30;299(4):425-36. doi: 10.1001/jama.299.4.425.

8.

Cell cycle proteins predict recurrence in stage II and III colon cancer.

Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tijssen M, van Essen DF, Heymans MW, Beliën JA, Stockmann HB, Meijer S, Meijer GA.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S682-92. doi: 10.1245/s10434-012-2216-7. Epub 2012 Feb 4.

PMID:
22311118
9.

Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer.

Yu G, Tang JQ, Tian ML, Li H, Wang X, Wu T, Zhu J, Huang SJ, Wan YL.

J Surg Oncol. 2012 Sep 1;106(3):232-7. doi: 10.1002/jso.22138. Epub 2011 Nov 7.

PMID:
22065543
10.

Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.

Weissmann-Brenner A, Kushnir M, Lithwick Yanai G, Aharonov R, Gibori H, Purim O, Kundel Y, Morgenstern S, Halperin M, Niv Y, Brenner B.

Int J Oncol. 2012 Jun;40(6):2097-103. doi: 10.3892/ijo.2012.1403. Epub 2012 Mar 16.

PMID:
22426940
11.

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.

12.

A Long Non-coding RNA Activated by Transforming Growth Factor-β is an Independent Prognostic Marker of Gastric Cancer.

Saito T, Kurashige J, Nambara S, Komatsu H, Hirata H, Ueda M, Sakimura S, Uchi R, Takano Y, Shinden Y, Iguchi T, Eguchi H, Ehata S, Murakami K, Sugimachi K, Mimori K.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S915-22. doi: 10.1245/s10434-015-4554-8. Epub 2015 May 19.

PMID:
25986864
13.

Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence.

Alaiyan B, Ilyayev N, Stojadinovic A, Izadjoo M, Roistacher M, Pavlov V, Tzivin V, Halle D, Pan H, Trink B, Gure AO, Nissan A.

BMC Cancer. 2013 Apr 17;13:196. doi: 10.1186/1471-2407-13-196.

14.

Associations of deregulation of mir-365 and its target mRNA TTF-1 and survival in patients with NSCLC.

Sun R, Liu Z, Ma G, Lv W, Zhao X, Lei G, Xu C.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2392-9. eCollection 2015.

15.

MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.

Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S, Seo AN, Lee HJ, Park SY.

Breast Cancer Res Treat. 2014 Aug;147(1):39-49. doi: 10.1007/s10549-014-3069-5. Epub 2014 Aug 3.

PMID:
25086633
16.

IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.

Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, Peng Z.

Ann Surg Oncol. 2009 Dec;16(12):3499-506. doi: 10.1245/s10434-009-0648-5.

PMID:
19672661
17.

Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.

Schetter AJ, Nguyen GH, Bowman ED, Mathé EA, Yuen ST, Hawkes JE, Croce CM, Leung SY, Harris CC.

Clin Cancer Res. 2009 Sep 15;15(18):5878-87. doi: 10.1158/1078-0432.CCR-09-0627. Epub 2009 Sep 8.

18.

Prognostic significance of miR-205 in endometrial cancer.

Karaayvaz M, Zhang C, Liang S, Shroyer KR, Ju J.

PLoS One. 2012;7(4):e35158. doi: 10.1371/journal.pone.0035158. Epub 2012 Apr 13.

19.

Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.

Pak MG, Lee CH, Lee WJ, Shin DH, Roh MS.

Diagn Pathol. 2015 Jul 12;10:99. doi: 10.1186/s13000-015-0339-4.

20.

miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.

Kim TH, Song JY, Park H, Jeong JY, Kwon AY, Heo JH, Kang H, Kim G, An HJ.

Cancer Lett. 2015 Jan 28;356(2 Pt B):937-45. doi: 10.1016/j.canlet.2014.11.011. Epub 2014 Nov 10.

PMID:
25444913

Supplemental Content

Support Center